Devin Quinlan
Directeur/Bestuurslid bij Nextpoint Therapeutics, Inc.
Profiel
Devin Quinlan is a Principal on the investment team at MPM BioImpact, where he is focused primarily on early-stage investment and company creation.
Since joining MPM BioImpact, Devin has been involved in multiple investments, including Orna Therapeutics as well as stealth companies in gene editing, platform chemistry, and precision oncology.
Additionally, Devin serves on the Board of Directors of Nextpoint Therapeutics and as a Board Observer at Crossbow Therapeutics, and he also supports a number of MPM BioImpact’s strategic relationships.
Devin completed his Ph.D.
in Biological Engineering at the Massachusetts Institute of Technology (MIT).
His thesis was focused on uncovering structure-function relationships of antibodies which target viral antigens, including Ebola and Zika viruses.
In addition to his academic research, Devin served as part of the inaugural leadership team of the MIT Biotech Group, which has since grown into the largest life-sciences student organization at MIT.
Devin is originally from Fresno, CA, and received his undergraduate degree in Bioengineering from the University of California, Los Angeles.
In his free time, he loves indoor climbing and live comedy, and can occasionally be seen performing improv in theaters around the greater Boston area.
Actieve functies van Devin Quinlan
Bedrijven | Functie | Begin |
---|---|---|
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01-01-2023 |
Bioimpact Capital LLC
Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | - |
Nextpoint Therapeutics, Inc.
Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Directeur/Bestuurslid | 01-01-2023 |
Opleiding van Devin Quinlan
University of California | Undergraduate Degree |
Massachusetts Institute of Technology | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Bioimpact Capital LLC
Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Nextpoint Therapeutics, Inc.
Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Commercial Services |